2 August 2017 (Wednesday) - ASH Newsletter

The August A.S.H. newsletter arrived in my inbox this morning. Several snippets of interest – my attention was particularly taken by the thingy on coagulation inhibitors. Nothing really new, but it reminded me of that which I’d forgotten. I need to remind myself about them

Editor's Corner
Keith Stewart, MBChB, MBA, acknowledges the hard work of every member of the “medical marvels” team – including Big Pharma.
The Geography of Drug Approvals
Why do regulatory agencies, such as the U.S. Food and Drug Administration and European Medicines Agency, look at the same data and get different results?

A Cure for Congress?
Jason Westin, MD, shares why he decided to run for Representative of the 7th Congressional District of Texas and how he’s navigating the challenges of balancing politics and patients.
Patient Education: Understanding Inhibitors
Produced in collaboration with the World Federation of Hemophilia, this tear sheet provides patients with information about the development, diagnosis, and treatment of hemophilia with inhibitors.
The Society Pages
A look at the latest promotions, grants, and awards in the hematology/oncology community.
ASH Directions
ASH selects outstanding trainees for award programs, announces honorific award winners, and more.

Latest and Greatest
NIH reverses decision to cap funding to individual laboratories, pembrolizumab trials halted after patient deaths, and more.

On Location
Highlights from the EHA Annual Congress, including anticoagulant therapy in older patients with VTE risk, polatuzumab vedotin combination in DLBCL, and more.

Read the August issue.
NEWS, Cont'd
Written in Blood
The latest research from Blood, including:
    Blood Advances in a Different Vein
    Literature Scan
    Research from other top journals, including:
    You Make the Call
    How would you treat a patient with aplastic anemia who refuses transfusions for religious reasons?

    No comments:

    Post a Comment